Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

The firm will track the activity of the triplet broadly in AML patients, including in those with FLT3, NRAS, and TP53 mutations.

Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies ...

Institutional investors own 67.78% of the company’s stock. Erasca, Inc, a clinical-stage precision oncology company, focuses ...

When this occurs, the affected children must be operated on at an early age. In the search for the cause of CPAM, the research team pursued the following hypothesis: Variants in cancer-associated ...

LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, and the Hamoui Foundation are proud to announce the recipients of the Hamoui Foundation/LUNGevity Clinical ...

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...

Fintel reports that on November 18, 2024, Jefferies initiated coverage of Erasca (NasdaqGS:ERAS) with a Buy recommendation.

Erasca, Inc. ( (ERAS) ) has released its Q3 earnings. Here is a breakdown of the information Erasca, Inc. presented to its investors. Erasca, ...

Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 ...

12, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS ...